Abstract
Behçet’s syndrome is an idiopathic multisystem inflammatory disease, most commonly involving orogenital mucosa and the skin. Some ethnicities and genetic backgrounds are more likely to develop Behçet’s syndrome, and human leukocyte antigen (HLA)-B51 is associated with some clinical phenotypes of the disease. Neuro-Behçet’s syndrome most commonly manifests as intracranial venous sinus thrombosis or multifocal subacute parenchymal lesions with pyramidal, cerebellar, and cranial nerve manifestations. The treatment of neuro-Behçet’s syndrome is based on use of corticosteroid for monophasic involvement and additional use of immunosuppressants or anti-tumor necrosis factor (TNF)α agents for relapsing or refractory disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Behçet H. Uber rezidivierende aphthöse, duruch ein virus verursachte geschwüre am mund am auge und an den genitalien. Dermatol Wochenschr. 1937;105:1151.
Davatchi F, Chams-Davatchi C, Shams H, Nadji A, Faezi T, Akhlaghi M, et al. Adult Behcet’s disease in Iran: analysis of 6075 patients. Int J Rheum Dis. 2016;19:95–103.
International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease Lancet (London, England). 1990;335:1078–1080.
Davatchi F, Assaad-Khalil S, Calamia KTT, Crook JEE, Sadeghi-Abdollahi B, Schirmer M, et al. The international criteria for Behçet’s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatology Venereol. 2014;28:338–47.
Yazici H, Seyahi E, Hatemi G, Yazici Y. Behçet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14:107–19.
McGonagle D, Aydin SZ, Gül A, Mahr A. “MHC-I-opathy”—unified concept for spondyloarthritis and Behçet disease. Nat Publ Group. 2015;11:731–40.
Lule S, Colpak AI, Balci-Peynircioglu B, Gursoy-Ozdemir Y, Peker S, Kalyoncu U, et al. Behçet disease serum is immunoreactive to neurofilament medium which share common epitopes to bacterial HSP-65, a putative trigger. J Autoimmun. 2017;84:87–96.
Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A. Relationships of HLA-B51 or B5 genotype with Behcet’s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford). 2012;51:887–900.
Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. Genome-wide association analysis identifies new susceptibility loci for Behçet’s disease and epistasis between HLA-B∗51 and ERAP1. Nat Genet. 2013;45:202–7.
Conde-Jaldón M, Montes-Cano MA, García-Lozano JR, Ortiz-Fernández L, Ortego-Centeno N, González-León R, et al. Epistatic interaction of ERAP1 and HLA-B in Behçet disease: a replication study in the Spanish population. PLoS One. 2014;9:e102100.
Ombrello MJ, Kirino Y, de Bakker PIW, Gül A, Kastner DL, Remmers EF. Behçet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity. Proc Natl Acad Sci U S A. 2014;111:8867–72.
Siva A, Saip S. The spectrum of nervous system involvement in Behçet’s syndrome and its differential diagnosis. J Neurol. 2009;256:513–29.
Yesilot N, Bahar S, Yılmazer S, et al. Cerebral venous thrombosis in Behçet’s disease compared to those associated with other etiologies. J Neurol. 2009;256:1134–42. https://doi.org/10.1007/s00415-009-5088-4.
Chan TY, Parwani AV, Levi AW, Ali SZ. Mollaret’s meningitis: cytopathologic analysis of fourteen cases. Diagn Cytopathol. 2003;28:227–31.
Al-Araji A, Kidd DP. Neuro-Behçet’s disease: epidemiology, clinical characteristics, and management. Lancet Neurol (Elsevier Ltd). 2009;8:192–204.
Saip S, Akman-Demir G, Siva A. Neuro-Behçet syndrome. Handb Clin Neurol. 2014;121:1703–23.
Zeydan B, Uygunoglu U, Saip S, Demirci ON, Seyahi E, Ugurlu S, et al. Infliximab is a plausible alternative for neurologic complications of Behçet disease. Neurol Neuroimmunol Neuroinflamm. 2016;3:e258.
Vitale A, Emmi G, Lopalco G, Gentileschi S, Silvestri E, Fabiani C, et al. Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study. Clin Rheumatol. 2017;36:451–5.
Greco A, De Virgilio A, Ralli M, Ciofalo A, Mancini P, Attanasio G, et al. Behçet’s disease: new insights into pathophysiology, clinical features and treatment options. Autoimmun Rev. 2018;17:567–75.
Sfikakis PP, Arida A, Panopoulos S, Fragiadaki K, Pentazos G, Laskari K, et al. Brief report: drug-free long-term remission in severe Behçet’s disease following withdrawal of successful anti-tumor necrosis factor treatment. Arthritis Rheumatol (Hoboken, NJ). 2017;69:2380–5.
Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;77:annrheumdis-2018-213225.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Gholipour, T., Siva, A. (2019). Neuro-Behçet’s Syndrome. In: Cho, T., Bhattacharyya, S., Helfgott, S. (eds) Neurorheumatology. Springer, Cham. https://doi.org/10.1007/978-3-030-16928-2_14
Download citation
DOI: https://doi.org/10.1007/978-3-030-16928-2_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-16927-5
Online ISBN: 978-3-030-16928-2
eBook Packages: MedicineMedicine (R0)